Categories Earnings, Health Care

Key factors to note when Pfizer (PFE) reports Q4 earnings results

Pfizer Inc. (NYSE: PFE) is scheduled to report fourth quarter 2019 earnings results on Tuesday, January 28, before the market opens. Both revenue and earnings are expected to be lower than the numbers reported in the year-ago period.

Analysts have forecast earnings of $0.57 per share which is lower than $0.64 reported last year. Revenues are expected to drop 9% to $12.61 billion.

Pfizer reports Q3 2019 earnings results

The company’s key products Ibrance, Xeljanz, Eliquis and Inlyta can be expected to continue their momentum in the fourth quarter boosting growth in the Biopharma segment. However, it remains to be seen if the weakness in Enbrel and Prevnar 13 will continue in the to-be-reported quarter.    

The Upjohn division has seen weak revenues due to volume declines and generic competition for some of its products. It remains to be seen if this trend carries on into the fourth quarter as well.

Pfizer has received several FDA approvals during the quarter including the approval of biosimilar ABRILADA for the treatment of multiple inflammatory conditions as well as XELJANZ XR extended release tablets for ulcerative colitis. Updates on this area will be worth watching.

Also read: Pfizer Q3 2019 Earnings Conference Call Transcript

Another topic to note will be updates on the combination of Mylan NV (NASDAQ: MYL) and Upjohn, which is anticipated to be completed in mid-2020.  

In the third quarter of 2019, Pfizer topped market expectations despite posting declines in the top and bottom line numbers. Revenues fell 5% to $12.7 billion while adjusted EPS dropped 2% to $0.75. Revenues in the Biopharma segment increased 7% while the Upjohn and Consumer Healthcare divisions saw sales declines of 28% and 55% respectively.

For the full year of 2019, Pfizer has guided for revenues of $51.2 billion to $52.2 billion and adjusted EPS of $2.94 to $3.00.

Shares of Pfizer have declined 5% in the past one year. The stock has an average price target of $41.26.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Key highlights from Autodesk (ADSK) Q4 2021 earnings results

Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per

Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%

Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus

Virgin Galactic stock tanks on delayed test flight

Virgin Galactic (NYSE: SPCE) reported fourth-quarter 2020 financial results after the regular market hours on Thursday. The space tourism company reported zero revenue in the fourth quarter, compared to $529,000

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top